It has been about a month since the last earnings report for Wex (WEX) . Shares have lost about 2.6% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Wex due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.WEX Q2 Earnings Beat EstimatesWEX reported impressive second-q ...

A month has gone by since the last earnings report for Quest Diagnostics (DGX) . Shares have added about 8.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Quest Diagnostics due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Quest Diagnostics Incorporated before we dive into how investors and analysts have reacted as of late.Quest ...

公司表现 - Accuray股价在过去一个月上涨约17%，表现优于标普500指数[1] - 公司近期增长评分为A，动量评分为C，价值评分为B，综合VGM评分为A[3] - Accuray的Zacks评级为3（持有），预计未来几个月回报率与市场持平[4] 财务数据与预期 - Accuray过去一个月的共识预期下调60%[2] - 行业同行Edwards Lifesciences同期股价上涨3.4%[5] - Edwards Lifesciences上季度营收14.1亿美元，同比下滑11.6%，每股收益0.64美元，低于去年同期的0.66美元[5] - Edwards Lifesciences当前季度预期每股收益0.62美元，同比下滑11.4%，过去30天共识预期微调+0.2%[6] 行业对比 - Accuray所属医疗仪器行业，同行Edwards Lifesciences的VGM评分为F，Zacks评级同样为3（持有）[6] - 两家公司均面临盈利预期下调趋势，但Accuray的综合评分显著优于同行[3][6]

股价表现 - 公司股价在过去一个月上涨12.1%，表现优于标普500指数[1] 盈利预测 - 过去一个月内市场对公司盈利预测呈上升趋势，共识预期上调20.03%[2] 投资评分 - 公司成长性评分为B级，但动量评分仅为F级，价值评分D级（处于同类后40%）[3] - 综合VGM评分为D级，显示多维度投资策略下的整体表现欠佳[3] 市场展望 - 盈利预测持续上修且幅度显著，公司获Zacks评级1级（强力买入）[4] - 预计未来数月股票回报率将高于市场平均水平[4]

股价表现 - 公司股价在过去一个月上涨7.9%，但表现逊于标普500指数[1] 盈利预测 - 过去一个月盈利预测未出现调整[2] - 共识预期因调整变化了5.01%[2] 投资评分 - 公司增长评分为F，动量评分为A[3] - 价值评分为B，位于该投资策略前40%[3] - 综合VGM评分为C[3] 展望 - 公司Zacks评级为3（持有）[4] - 预计未来几个月股票回报将与市场持平[4]